Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

IF 20.4 1区 医学 Q1 CLINICAL NEUROLOGY
Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera
{"title":"Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.","authors":"Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera","doi":"10.1001/jamaneurol.2025.0495","DOIUrl":null,"url":null,"abstract":"Importance\r\nProgression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.\r\n\r\nObjective\r\nTo compare various definitions of PIRA.\r\n\r\nDesign, Setting, and Participants\r\nThis cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.\r\n\r\nExposure\r\nThree-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).\r\n\r\nMain Outcome and Measure\r\nFor each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).\r\n\r\nResults\r\nAmong 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.\r\n\r\nConclusion and Relevance\r\nIncidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"121 1","pages":""},"PeriodicalIF":20.4000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaneurol.2025.0495","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Importance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.
复发缓解型多发性硬化症中独立于复发活动的进展(PIRA)的标准化定义。
独立于复发活动的进展(PIRA)是复发-缓解型多发性硬化症(MS)长期残疾积累的重要因素。先前的研究使用了不同的PIRA定义,阻碍了研究结果的可比性。目的比较PIRA的不同定义。设计、环境和参与者本队列研究对2004年7月至2023年7月期间MSBase注册表前瞻性收集的数据进行回顾性分析。参与者是来自43个国家186个中心的多发性硬化症患者,他们有临床明确的复发-缓解型多发性硬化症,一个完整的最小数据集,以及3个或更多记录的扩展残疾状态量表(EDSS)评估。暴露有三百六十种将PIRA定义为下列标准的组合:基线残疾(固定基线,PIRA后重新基线,或复发后重新基线,或改善后重新基线),最短确认期(6、12或24个月),确认幅度(EDSS评分达到/高于恶化评分或与基线相比达到/高于阈值),EDSS评分恶化时无复发(90天前,90天前和30天后,180天前和之后,自上次EDSS评估以来,或自基线以来),确认时(30天前,90天前,前后30天,或恶化与确认之间)无复发。对于每个定义,我们量化了PIRA的发生率和持续性(即,在≥5年内没有3个月的EDSS改善)。结果87 239例MS患者中,33 303例符合纳入标准;24例 ,女性152例(72.5%),男性9151例(27.5%)。初诊时平均(SD)年龄为36.4(10.9)岁;28 052例(84.2%)患者为复发缓解型MS,中位(IQR) EDSS评分为2.0(1.0-3.0)。参与者在8.9年(5.2年)的时间里平均(SD)为15.1次(11.9次)。根据定义,PIRA发生率为每10年0.141 ~ 0.658次,持续时间为0.753 ~ 0.919次。特别是基线和确认期影响PIRA的检测。以下定义获得了发生率和持续性的平衡:与基线(每次PIRA事件、复发和EDSS评分改善后重置)相比,显著的残疾恶化,自上次EDSS评估以来没有复发,EDSS评分证实(之前30天内没有复发)保持在恶化阈值以上至少12个月。结论与相关性PIRA的发生率和持续性取决于所使用的定义。提出的标准化定义旨在提高研究之间的可比性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JAMA neurology
JAMA neurology CLINICAL NEUROLOGY-
CiteScore
41.90
自引率
1.70%
发文量
250
期刊介绍: JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system. The Archives of Neurology & Psychiatry began publication in 1919 and, in 1959, became 2 separate journals: Archives of Neurology and Archives of General Psychiatry. In 2013, their names changed to JAMA Neurology and JAMA Psychiatry, respectively. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信